Interplay of Chronic Kidney Disease and the Effects of Tirzepatide in Patients With Heart Failure, Preserved Ejection Fraction, and Obesity: The SUMMIT Trial

What Was Tested

Researchers studied Tirzepatide in this randomized controlled trial publication.

This analysis had dual objectives: 1) to evaluate the influence of CKD on the clinical responses to tirzepatide in patients with obesity-related HFpEF; and 2) to investigate the complexity of tirzepatide-related changes in renal function.

For both objectives, the researchers focused on discrepancies between creatinine-based and cystatin C-based estimates of the estimated glomerular filtration rate (eGFR).

Why It Was Studied

Obesity leads to both heart failure with a preserved ejection fraction (HFpEF) and to chronic kidney disease (CKD); CKD may both influence the clinical course of obesity-related HFpEF; and incretin-based drugs may influence renal function.

Who Took Part

According to the abstract, 731 patients were involved.

By PubMed's age tags, the people studied were middle-aged adults and older adults, both men and women.

The SUMMIT trial randomly assigned 731 patients with HFpEF and a body mass index ≥30 kg/m2, who were enriched for participants with CKD.

How the Study Was Run

The researchers set it up as a randomized and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got Tirzepatide and who got the comparison, which limits bias.

Some patients received a placebo instead of Tirzepatide, giving a reference point.

Because of the confounding produced by obesity and changes in muscle mass, eGFR was assessed at randomization and after 12, 24, and 52 weeks by both creatinine-based and cystatin C-based formulae.

What Was Measured

PubMed files the paper under topics including Heart Failure, Obesity, Renal Insufficiency, Chronic, Stroke Volume, Glomerular Filtration Rate, Cystatin C and Sodium-Glucose Transporter 2 Inhibitors.

The authors tagged it with the keywords chronic kidney disease and heart failure and preserved ejection fraction.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Tirzepatide in 731 patients.

With several hundred people or more, it is a fairly large study for this kind of research.

Results are reported in around 8 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2025 (Journal of the American College of Cardiology), a journal based in United States.

More context: the Tirzepatide compound page, all human trials.